CH633716A5 - Method for separating and purifying products having interferon activity, purified preparations having interferon activity and use of the preparations - Google Patents
Method for separating and purifying products having interferon activity, purified preparations having interferon activity and use of the preparations Download PDFInfo
- Publication number
- CH633716A5 CH633716A5 CH473978A CH473978A CH633716A5 CH 633716 A5 CH633716 A5 CH 633716A5 CH 473978 A CH473978 A CH 473978A CH 473978 A CH473978 A CH 473978A CH 633716 A5 CH633716 A5 CH 633716A5
- Authority
- CH
- Switzerland
- Prior art keywords
- interferon
- products
- preparations
- interferon activity
- buffer
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims description 184
- 108010050904 Interferons Proteins 0.000 title claims description 184
- 229940079322 interferon Drugs 0.000 title claims description 183
- 238000002360 preparation method Methods 0.000 title claims description 107
- 230000000694 effects Effects 0.000 title claims description 83
- 238000000034 method Methods 0.000 title claims description 60
- 102000040430 polynucleotide Human genes 0.000 claims description 91
- 108091033319 polynucleotide Proteins 0.000 claims description 91
- 239000002157 polynucleotide Substances 0.000 claims description 87
- 239000000872 buffer Substances 0.000 claims description 48
- 238000003795 desorption Methods 0.000 claims description 32
- 239000003463 adsorbent Substances 0.000 claims description 26
- 239000003446 ligand Substances 0.000 claims description 25
- 239000007787 solid Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 229920000936 Agarose Polymers 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 229920002477 rna polymer Polymers 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 229920002521 macromolecule Polymers 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000012149 elution buffer Substances 0.000 claims description 3
- 125000003367 polycyclic group Chemical group 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229940028843 inosinic acid Drugs 0.000 claims description 2
- 239000004245 inosinic acid Substances 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 150000004804 polysaccharides Polymers 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000000047 product Substances 0.000 description 85
- 229920002684 Sepharose Polymers 0.000 description 58
- 239000000499 gel Substances 0.000 description 36
- 229920002307 Dextran Polymers 0.000 description 32
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000010168 coupling process Methods 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 15
- 230000008878 coupling Effects 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000001179 sorption measurement Methods 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 238000001042 affinity chromatography Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 241000711404 Avian avulavirus 1 Species 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 238000011403 purification operation Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
- QLZOWJNFLXSDSH-UHFFFAOYSA-N 4-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]butanamide Chemical compound COCCCC(=O)NCC1=CC=C(C(F)(F)F)C=C1 QLZOWJNFLXSDSH-UHFFFAOYSA-N 0.000 description 1
- DOBIZWYVJFIYOV-UHFFFAOYSA-N 7-hydroxynaphthalene-1,3-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=CC(O)=CC=C21 DOBIZWYVJFIYOV-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000000993 Dendritic Keratitis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7713255A FR2389380B1 (enrdf_load_stackoverflow) | 1977-05-02 | 1977-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH633716A5 true CH633716A5 (en) | 1982-12-31 |
Family
ID=9190209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH473978A CH633716A5 (en) | 1977-05-02 | 1978-05-02 | Method for separating and purifying products having interferon activity, purified preparations having interferon activity and use of the preparations |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS53139714A (enrdf_load_stackoverflow) |
| CH (1) | CH633716A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2819297A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2389380B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1601744A (enrdf_load_stackoverflow) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN150740B (enrdf_load_stackoverflow) * | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
| FI77877C (fi) * | 1979-04-20 | 1989-05-10 | Technobiotic Ltd | Foerfarande foer framstaellning och rening av human le-formig interferonprotein. |
| US6410697B1 (en) | 1979-04-20 | 2002-06-25 | Schering Corporation | Process for purifying human leukocyte interferon |
| US4278661A (en) * | 1979-10-12 | 1981-07-14 | E. I. Du Pont De Nemours And Company | Purification of interferon |
| US4362155A (en) * | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
-
1977
- 1977-05-02 FR FR7713255A patent/FR2389380B1/fr not_active Expired
-
1978
- 1978-05-02 CH CH473978A patent/CH633716A5/fr not_active IP Right Cessation
- 1978-05-02 GB GB17225/78A patent/GB1601744A/en not_active Expired
- 1978-05-02 JP JP5243578A patent/JPS53139714A/ja active Pending
- 1978-05-02 DE DE19782819297 patent/DE2819297A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB1601744A (en) | 1981-11-04 |
| DE2819297A1 (de) | 1978-11-16 |
| JPS53139714A (en) | 1978-12-06 |
| FR2389380A1 (enrdf_load_stackoverflow) | 1978-12-01 |
| FR2389380B1 (enrdf_load_stackoverflow) | 1980-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0259197A1 (fr) | Conjugués macromuléculaires d'hémoglobine leur procédé de préparation et leurs applications | |
| FI60501C (fi) | Foerfarande foer selektiv separering av interferon fraon interferon-raopreparat | |
| CH658669A5 (fr) | Derives d'activateurs du plasminogene. | |
| JPH0480886B2 (enrdf_load_stackoverflow) | ||
| CH664974A5 (fr) | Production du facteur de lyse des cellules-cibles. | |
| LU84662A1 (fr) | Nouvelles glycoproteines,procedes pour leur preparation et agents therapeutiques contenant ces glycoproteines en vue de combattre les tumeurs | |
| EP0402205B1 (fr) | Procédé de préparation de solutions d'albumine purifiée | |
| US20030166513A1 (en) | Dds compound and process for the preparation thereof | |
| HUT72750A (en) | Method for preparing thioether conjugates | |
| EP3481415A1 (fr) | Fibrinogène liquide stable | |
| CH633716A5 (en) | Method for separating and purifying products having interferon activity, purified preparations having interferon activity and use of the preparations | |
| CH664969A5 (fr) | Lymphokine humain, sa production et son utilisation pour obtenir un anticorps monoclonal specifique de ce lymphokine. | |
| FR2522001A1 (fr) | Polysaccharides, leur preparation et compositions therapeutiques contenant ces produits | |
| CH639396A5 (fr) | Substance dite ''ks-2-b'' et procede pour sa fabrication. | |
| CA1295985C (fr) | Procede pour la separation et la purification des antigenes proteiques des bacteries du genre bordetella | |
| EP1328546B1 (fr) | Cyclopeptides, leur procede de preparation et leur utilisation comme inhibiteur ou activateur de l'angiogenese | |
| EP0557199A1 (fr) | Conjugés polyéthylèneglycol-hirudine, leur procédé de préparation et leur emploi pour le traitement des thromboses | |
| JPH03501085A (ja) | 化学的プロセス | |
| EP0242301B1 (fr) | Procédé de purification d'antigènes protéiques de bactéries appartenant au genre Bordetella, en vue de l'obtention d'un vaccin acellulaire | |
| FR2466252A2 (fr) | Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine | |
| EP0041019B1 (fr) | Nouveaux produits préparés à partir du facteur thymique sérique ou de ses analogues et dérivés, procédé de préparation de ces produits, ces produits pour utilisation comme médicaments, traceurs obtenus à partir de ces produits et utilisation de ces traceurs dans des procédés de dosage | |
| FR2838649A1 (fr) | Composition anti-vih, procede de fabrication et medicament | |
| CH664574A5 (fr) | Lymphokine et anticorps monoclonal specifique de ce lymphokine, leurs production et utilisations. | |
| CS216547B2 (en) | Method of production of the proteinous factor | |
| JPH05503006A (ja) | ヒトｂＦＧＦムテインの製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |